Cover Image
Market Research Report

Merck KGaA Company Analysis

Published by Datamonitor Healthcare Product code 603918
Published Content info 50 Pages
Delivery time: 1-2 business days
Back to Top
Merck KGaA Company Analysis
Published: August 24, 2018 Content info: 50 Pages

PharmaVitae explores Merck KGaA's prescription pharmaceutical performance and outlook over 2017-27. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.


  • Overview - Merck KGaA's sparse late-stage pipeline and exposure to generics mean an increased reliance on its PD-L1 therapy Bavencio.
  • Key themes - [1] Merck KGaA's revenue continues to be negatively impacted by branded and generic competition to its portfolio of longer-listed products [2] Merck KGaA is attempting to combat these sales declines through its foray into the lucrative immuno-oncology market, and the launch of Mavenclad in multiple sclerosis [3] The company's CNS portfolio will decline at a CAGR of -1.8% out to 2027 as it loses prominence in multiple sclerosis [4] Oncology will be a key growth driver for Merck KGaA, growing at a 3.0% CAGR out to 2027 [5] Merck KGaA's outlook remains highly dependent on the successful further development of Bavencio.
  • Q1 2018 - Merck KGaA reports weak sales exacerbated by currency headwinds.
  • Out to 2022 - The expiries of longer-listed products will be partially offset by the 2017 launch of Bavencio, and growth in emerging markets.
  • Out to 2027 - The company will add $194m out to 2027, owing to growth in its oncology and metabolic portfolios, and the launch of Mavenclad.
  • Pipeline - Merck KGaA currently has no new molecular entity drugs in clinical development, and is heavily reliant on label expansions for Bavencio and Mavenclad.
  • Lifecycle - Merck KGaA's launch portfolio, focused on Bavencio and Mavenclad, will be sufficient in offsetting its principal pharma declines.
  • Major events - Bavencio will continue its expansion across solid tumor types as Mavenclad seeks approval in the US for multiple sclerosis.

Model updates

  • Reduced RoW sales owing to currency headwinds.
  • Merck KGaA acquires the rights to abituzumab from SFJ.
  • Divestiture of consumer healthcare business.

Analysis structure

  • Explore and visualize revenue dynamics in Merck KGaA's portfolio out to 2027 using 10-year in-house sales forecasts segmented by the following sections.

Quarterly review

  • What were the major highlights from Merck KGaA's latest earnings call and quarterly performance?

Strategy analysis

  • How is Merck KGaA strategically poised out to 2027?
  • What are Merck KGaA's key strengths, weaknesses, opportunities, and threats?
  • What are Merck KGaA's key catalysts during the current year?

Portfolio analysis

  • Why will specific therapy areas experience the largest growth and decline?
  • What are the detailed competitive dynamics at play in Merck KGaA's important therapeutic markets?
  • How is Merck KGaA adapting strategically to internal and external headwinds in preceding quarters?

Facts and figures

  • What is Merck KGaA's forecasted sales performance out to 2027?
  • What is the revenue trajectory of Merck KGaA's current top 10 products out to 2027?
  • Which therapy areas will experience the largest growth and decline?
  • What are the portfolio weightings of Merck KGaA based on the lifecycle of its products?
Table of Contents
Product Code: DMKC0200044



  • Snapshot
  • Model updates
  • Analysis structure

Q2 2018 REVIEW

  • Merck KGaA's healthcare revenue reaches a new low
  • Bibliography

Q1 2018 REVIEW

  • Merck KGaA reports weak sales exacerbated by currency headwinds
  • A negative exchange rate sharply impacts healthcare revenue Q1 2018 highlights
  • Q1 2018 highlights
  • Mid-stage clinical potential
  • Bibliography

Q4 2017 REVIEW

  • Merck KGaA healthcare revenues grow by 2% in 2017 amid strong competitive pressures
  • Core products show organic decline amid strong competitive challenges
  • Bavencio development setbacks
  • Mavenclad launch strengthens Merck KGaA's presence in MS
  • Bibliography

Q3 2017 REVIEW

  • Merck KGaA reports falling revenues due to pressures to Rebif and Erbitux
  • Bavencio approvals in Merkel cell carcinoma
  • Mavenclad approval in Europe
  • Divestment of businesses
  • Q3 2017 events
  • Bibliography


  • Healthcare focus
  • Full-year 2017 results
  • Key priorities outlined for 2018
  • Net debt to EBITDA ratio
  • Divestment of businesses
  • Merck KGaA's SWOT analysis
  • Merck KGaA's key events and catalysts
  • Bibliography


Q2 2018


  • Merck KGaA's prescription pharma sales outlook
  • Merck KGaA's regional pharma sales outlook
  • Merck KGaA's therapy area dynamics
  • Merck KGaA's growth drivers and resistors
  • Merck KGaA's portfolio lifecycle analysis
  • Merck KGaA's pipeline analysis
  • Merck KGaA's M&A strategy and history
  • Bibliography


  • Figure 1: Merck KGaA's prescription pharmaceutical sales ($m) and growth rate (%), 2014-27
  • Figure 2: Merck KGaA's therapy area dynamics, 2017-27
  • Figure 3: Merck KGaA's launch/core/expiry portfolio configuration, 2017-27
  • Figure 4: Merck KGaA's pipeline overview


  • Table 1: Merck KGaA's established core product quarterly sales (€m)
  • Table 2: Merck KGaA's sales by therapy area ($m), 2017-27
  • Table 3: Merck KGaA's prescription pharmaceutical sales by region ($m), 2017-27
  • Table 4: Merck KGaA's sales by therapy area ($m), 2017-27
  • Table 5: Merck KGaA's CNS portfolio sales, by product ($m), 2017-27
  • Table 6: Merck KGaA's oncology portfolio sales, by product ($m), 2017-27
  • Table 7: Merck KGaA's key products, 2017-27
  • Table 8: Merck KGaA's sales by launch, core, and expiry portfolio ($m), 2017-27
  • Table 9: Merck KGaA's launch portfolio sales, by product ($m), 2017-27
  • Table 10: Merck KGaA's key merger and acquisition deals, 2003-18
Back to Top